The stakes are high for psilocybin clinical trials — there’s a pressing need for a more effective medical solution in the ...
Two doses of psilocybin, the active ingredient in “magic mushrooms,” against a six-week course of the popular antidepressant ...
A study published in Nature Neuroscience suggests that targeting specific brain circuits with non-invasive neurostimulation ...
Who was Elisabeth Finch? The true story of the Grey's Anatomy writer who lied about having cancer of the bone.
Zacks Small Cap Research on MSN1d
MIRA Continues to Post Outstanding Test ResultsMIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...
A new study explores the dual nature of fear memories: difficult to forget but hard to recall. By using fMRI and machine ...
An innovative study, published in Nature Communications, reveals the mechanism behind two seemingly contradictory effects of ...
For many soldiers, the war against Hamas in Gaza is a fight for Israel’s survival and must be won by any means. But the ...
RTI International launched a randomized, controlled trial of SGB in 2014 and concluded in 2019 that the treatment "is indeed ...
New, non-hallucinogenic versions of psychedelics are blurring the boundaries of the drug trip.
A new study has shed light on why some children and adolescents develop mental health disorders like PTSD, anxiety, or depression after experiencing a traumatic event.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback